Advanced search
1 file | 356.65 KB Add to list

Angiopoietin-2 promotes pathological angiogenesis and is a novel therapeutic target in non-alcoholic fatty liver disease

Sander Lefere (UGent) , Frederique Van de Velde (UGent) , Anne Hoorens (UGent) , Sarah Raevens, Sanne Van Campenhout (UGent) , Astrid Vandierendonck (UGent) , Sara Neyt (UGent) , Bert Vandeghinste (UGent) , Christian Vanhove (UGent) , Charlotte Debbaut (UGent) , et al.
(2018) HEPATOLOGY. 68(suppl. 1). p.753A-753A
Author
Organization

Downloads

  • 8588262.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 356.65 KB

Citation

Please use this url to cite or link to this publication:

MLA
Lefere, Sander et al. “Angiopoietin-2 Promotes Pathological Angiogenesis and Is a Novel Therapeutic Target in Non-alcoholic Fatty Liver Disease.” Hepatology. Vol. 68. 2018. 753A–753A. Print.
APA
Lefere, Sander, Van de Velde, F., Hoorens, A., Raevens, S., Van Campenhout, S., Vandierendonck, A., Neyt, S., et al. (2018). Angiopoietin-2 promotes pathological angiogenesis and is a novel therapeutic target in non-alcoholic fatty liver disease. HEPATOLOGY (Vol. 68, p. 753A–753A). Presented at the Annual meeting of the American Association for the Study of Liver Diseases (AASLD) ; Liver meeting.
Chicago author-date
Lefere, Sander, Frederique Van de Velde, Anne Hoorens, Sarah Raevens, Sanne Van Campenhout, Astrid Vandierendonck, Sara Neyt, et al. 2018. “Angiopoietin-2 Promotes Pathological Angiogenesis and Is a Novel Therapeutic Target in Non-alcoholic Fatty Liver Disease.” In Hepatology, 68:753A–753A.
Chicago author-date (all authors)
Lefere, Sander, Frederique Van de Velde, Anne Hoorens, Sarah Raevens, Sanne Van Campenhout, Astrid Vandierendonck, Sara Neyt, Bert Vandeghinste, Christian Vanhove, Charlotte Debbaut, Xavier Verhelst, Jo Van Dorpe, Christophe Van Steenkiste, Christophe Casteleyn, Bruno Lapauw, Hans Van Vlierberghe, Anja Geerts, and Lindsey Devisscher. 2018. “Angiopoietin-2 Promotes Pathological Angiogenesis and Is a Novel Therapeutic Target in Non-alcoholic Fatty Liver Disease.” In Hepatology, 68:753A–753A.
Vancouver
1.
Lefere S, Van de Velde F, Hoorens A, Raevens S, Van Campenhout S, Vandierendonck A, et al. Angiopoietin-2 promotes pathological angiogenesis and is a novel therapeutic target in non-alcoholic fatty liver disease. HEPATOLOGY. 2018. p. 753A–753A.
IEEE
[1]
S. Lefere et al., “Angiopoietin-2 promotes pathological angiogenesis and is a novel therapeutic target in non-alcoholic fatty liver disease,” in HEPATOLOGY, San Francisco, CA, USA, 2018, vol. 68, no. suppl. 1, pp. 753A-753A.
@inproceedings{8600513,
  author       = {Lefere, Sander and Van de Velde, Frederique and Hoorens, Anne and Raevens, Sarah and Van Campenhout, Sanne and Vandierendonck, Astrid and Neyt, Sara and Vandeghinste, Bert and Vanhove, Christian and Debbaut, Charlotte and Verhelst, Xavier and Van Dorpe, Jo and Van Steenkiste, Christophe and Casteleyn, Christophe and Lapauw, Bruno and Van Vlierberghe, Hans and Geerts, Anja and Devisscher, Lindsey},
  booktitle    = {HEPATOLOGY},
  issn         = {0270-9139},
  language     = {eng},
  location     = {San Francisco, CA, USA},
  number       = {suppl. 1},
  pages        = {753A--753A},
  title        = {Angiopoietin-2 promotes pathological angiogenesis and is a novel therapeutic target in non-alcoholic fatty liver disease},
  volume       = {68},
  year         = {2018},
}

Web of Science
Times cited: